Andrew Allen
Co-founder, President and Chief Executive Officer
oncology
Gritstone Oncology
United States of America
Biography
Dr. Andrew Allen is a prime supporter of Gritstone Oncology and fills in as president, CEO and an individual from the top managerial staff. He was a fellow benefactor of Clovis Oncology where he filled in as official VP of clinical and preclinical advancement and boss therapeutic officer. Before that, he was boss therapeutic officer at Pharmion Corporation, which was sold to Celgene Corporation for $2.9 billion after the advancement of Vidaza™ for the treatment of myelodysplastic disorders and Thalomid™ for the bleeding edge treatment of various myeloma. Beforehand, Dr. Allen served in clinical improvement influential positions at Chiron Corporation and Abbott Laboratories, and worked at McKinsey and Company, where he exhorted life science organizations on vital issues. He presently serves on the governing body of Epizyme and Cell Design Labs. Dr. Allen got a medicinal degree from Oxford University and a Ph.D. in immunology from Imperial College London.
Research Interest
Superior Neoantigen Prediction, Immunogenic Antigen Delivery at Industrial Scale
